Orexigen Therapeutics — BIO Investor Forum 2017
32 slides from Orexigen Therapeutics's conference presentation, Oct 16, 2017
Slide 1: BIO Investor Forum
BIO Investor Forum Michael Narachi Chief Executive Officer October 17, 2017 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. and its Contrave® product. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,” “designed” and sim
Slide 3: Indication and Important Safety Information
Indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid conditio
Slide 4: Recent Patent Judgment provides exclusivity to 2030
Recent Patent Judgment provides exclusivity to 2030 Patent Claim Description Expiration Ruling 7,375,111 Fixed dose of bupropion SR and naltrexone SR for treatment of obesity 3/26/25 Favorable 7,462,626 Methods of treating obesity with a combination of bupropion and naltrexone 7/20/24 Favorable 8,91
Slide 5: Overall Business Performance: Key Takeaways
First year results after re-purchasing US rights from our former partner are very positive, with about half of the prior spend Aided by Orexigen’s consumer-focused campaign, Contrave achieved new all time highs in volume, share, and net revenue per Rx Learning from our first year of commercializatio
Slide 6: Contrave Weekly Market Share – All Time Market Share High
Contrave Weekly Market Share – All Time Market Share High Source: QuintilesIMS NPA Weekly, Week Ending 10/06/17 Contrave Belviq Qsymia Saxenda Note: Digital and Print Ads are still active after 2nd week of May Fall Campaign started 9/10
Slide 7: Contrave TRx Volume Approaching Prior Highs
Contrave TRx Volume Approaching Prior Highs, Responding Well to the Promotional Campaign Kicked Off in September Source: QuintilesIMS NPA Weekly, Week Ending 10/06/17 Contrave Belviq Qsymia Saxenda Note: Digital and Print Ads are still active after 2nd week of May Fall Campaign started 9/10 Orexigen
Slide 8: Contrave NBRx Volume has Jumped Nearly 70%
Source: QuintilesIMS Market Dynamics, Week Ending 9/29/17 Contrave NBRx Volume has Jumped Nearly 70% in Response to Recent Promotional Tactics (%) = NBRx as % of TRx Note: Digital and Print Ads are still active after 2nd week of May Fall Campaign started 9/10
Slide 9: We Project Strong Double Digit Growth of Contrave
We Project Strong Double Digit Growth of Contrave Source: IMS NPA; Orexigen estimates. U.S. TRx Volume
Slide 10: September 2017: Applying Our First-Year Learnings to Our Second Year
September 2017: Applying Our First-Year Learnings to Our Second Year
Slide 11: September 2017 Commercial Campaign
Plan to activate patients during the Fall season where “back to school, back to routine, back to you” themes can activate weight loss patients Focus patients on Telemedicine and Free Home Delivery via “Get Contrave Now” Main activity runs from mid August to mid October Key Elements of Plan: Fall Sea
Slide 12: End-to-end Telemedicine Process for Contrave
Orexigen is driving a fundamental change in the patient journey Branded Site: Contrave Digital Activation Broadcast TV * The online doctor consult and free home delivery services are offered by our partners Patient chooses preferred HCP interaction Patient Visits HCP Office Traditional eRx Patient P
Slide 13: New Call to Action for "Get Contrave Now"
New Call to Action for “Get Contrave Now” with getcontravenow.com URL that directs to contrave.com homepage – in all TV/Digital DTC ads Broadcast TV “Now you can talk to a doctor online and get free shipping at getcontravenow.com” (URL directs to homepage)
Slide 14: Revised TV Advertisement
Revised TV: “Now you can talk to a doctor online and get free shipping at getcontravenow.com” “Lose weight and keep it off with Contrave” “Contrave is believed to work on two areas of the brain: Your hunger center “I’m so hungry” to reduce hunger. And your reward system…”ice cream, French fries” to
Slide 15: Revised Digital Display 60-Second Video
Revised Digital Display 60-Second Video Revised 60-Second Video with “Get Contrave Now” is running across all partners currently Any place on both the video and banner is clickable throughout the entire video Targeting tactics include: Retargeting site visitors in last 30 days regardless of action t
Slide 16: New Social "Get Contrave Now" Ads
New Social “Get Contrave Now” Ads 16 The entire campaign incorporates key safety and risk information including the boxed warning for suicidal thoughts and behaviors
Slide 17: Fall Campaign: Early Results
Fall Campaign: Early Results
Slide 18: Fall Campaign - Key Performance Metrics
Fall Campaign - Key Performance Metrics Overall Performance TRx: Volume and Share NBRx: Volume and Share Therapy Starts Brand Switch Digital Performance Website Traffic: Volume and Source Key Actions: Volume and KA Rate FAD Page Views GCN Page Views Doctor Discussion Guide Page Views Savings Card Pa
Slide 19: Contrave.com traffic volume increased >80%
Contrave.com traffic volume increased >80% vs. the average of last the four weeks prior to September SOURCE: Google Analytics Off Season, No TV Avg. = 63K During TV Avg. = 130K Prior to Consumer Campaign Fall TV Campaign Started
Slide 20: Updated Call to Action increased Get Contrave Now Page Views
SOURCE: Google Analytics Updating the Call to Action has increased “Get Contrave Now” Page Views nearly 4X vs. the average volume in August Fall TV Campaign Started
Slide 21: Telemedicine and Home Delivery New Prescription and Refill Rates
Source: Orexigen Therapeutics Telemedicine and Home Delivery New Prescription and Refill Rates Supported by Customer Service Model Week Ending Contrave “Get Contrave Now” Fulfillments – New Rx and Refills Fall TV Campaign Started
Slide 22: Get Contrave Now fulfillments as % of TRx
Source: Orexigen Therapeutics, QuintilesIMS Get Contrave Now fulfillments as % of TRx Get Contrave Now Fulfillments Week Ending 8.8% Fall TV Campaign Started 3.8%
Slide 23: OUS Commercial Update
ts OREXIGEN OUS Commercial Update
Slide 24: Now Partnered in Countries Outside the U.S.
Now Partnered in 48 Countries Outside the U.S. South Korea Central & Eastern Europe Spain Canada Aus/ NZ South Africa 3Q 15 4Q 15 1Q 16 2Q 16 3Q 16 4Q 16 UK Ireland Middle East 2017 Goal: Add 10-15 additional countries, with a focus on Latin America and Europe 2Q 17 Italy 1Q 17 Nordics 3Q 17 Egypt A
Slide 25: Launched in 17 Countries Outside the U.S.
Submissions Launches 4Q 17 3Q 17 2Q 17 1Q 17 4Q 16 3Q 16 2Q 16 1Q 16 Saudi Arabia Lebanon UAE Kuwait Serbia South Africa Saudi Arabia Australia Canada Lebanon UAE Kuwait Greece United Kingdom Ireland Spain Bulgaria Estonia Lithuania Latvia Croatia Slovenia Korea Czech Republic Slovakia Hungary Polan
Slide 26: Preclinical Development Assets
Preclinical Development Assets Orex-1038: Chronic Pain Analgesic Orex-1019: Opioid Addiction Management
Slide 27: The Opioid Addiction Public Health Epidemic
259M opioid prescriptions in 2012 written for the 48M people treated It is estimated that only 10% of patients treated with prescription opioids develop dependence In 2014, the most recent year for which data is available, >10,000,000 individuals reported using prescription opioids non-medically and
Slide 28: Pain Management: Opioids Continue to be the Standard of Care
Sources: North America Opioid Market, Grand View Research Nahin, Richard L, Estimates of Pain Prevalence and Severity in Adults: United States, 2012 The Journal of Pain, Vol 16 No 8, August 2015 Pain Management: Opioids Continue to be the Standard of Care for Chronic Pain Management
Slide 29: Medication-Assisted Treatment of opioid addiction market
SUBOXONE® (buprenorphine/naloxone) film is the clear and established market leader, with >$1B in 2016 net sales. The naltrexone (Vivitrol®) market has been increasing at 40% annually, and generated net sales of >$200M in 2016. Medication-Assisted Treatment (MAT): Buprenorphine / Buprenorphine Combin
Slide 30: OREX-1038 Preclinical Asset: Profile and Key Data
OREX-1038 Preclinical Asset: Profile and Key Data Member of 25 molecule naltrexone analogue series exclusively licensed by Orexigen Novel partial agonist activity at Mu Opioid and Nociceptin receptors Significant, long-lasting analgesia in primates at doses >100x lower than Morphine Significant anal
Slide 31: OREX-1019 Preclinical Asset: Profile and Key Data
OREX-1019 Preclinical Asset: Profile and Key Data Member of 15-molecule novel orvinol series exclusively licensed by Orexigen Novel opioid receptor activity profile places OREX-1019 between buprenorphine and naltrexone as a opioid antagonist Significant inhibition of opioid (prescription and Heroin)
Slide 32: Overall Business Performance: Key Takeaways
First year results after re-purchasing US rights from our former partner are very positive, with about half of the prior spend Aided by Orexigen’s consumer-focused campaign, Contrave achieved new all time highs in volume, share, and net revenue per Rx Learning from our first year of commercializatio